‘If you've ever experienced it, you'd feel differently’: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States
Addiction · 2026-09 · 121 (9) · 2494-2503
DOI: 10.1111/add.70447 ↗At a glance
Journal article in Addiction, published online on 2026-04-29. Written by Laura N Sisson and 8 co-authors. Institution: Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. Major MEDLINE topics: Naloxone, Narcotic Antagonists, Drug Overdose, Opioid-Related Disorders. 46 references. The full text is freely available in PubMed Central. Funded by: Bloomberg American Health Initiative.
Abstract (original language)
Background and aims Higher dose naloxone products (HDN) have recently been approved and marketed in the United States; however, evidence on the relative advantage of these products to standard 4 mg products has not been substantiated by prior research. People who use drugs are the primary beneficiaries and consumers of naloxone products. This study aimed to characterize their willingness to use HDN products and technical understanding of these products. Design and measurements We conducted in‐depth interviews with syringe service program clients following an interview guide. Interviews were recorded and transcribed before being analyzed using a hybrid deductive‐inductive qualitative approach.
Setting
Interviews were conducted in partnership with community‐based syringe service programs in three distinct regions of the state of Maryland, USA: a rural county, Baltimore city and a surrounding suburban community.
Participants
Twenty‐two interviews were completed. All participants had used opioids and responded to an overdose using naloxone in the past 3 months. The majority of participants were men (73%), non‐Hispanic white (64%) and currently experiencing housing instability (59%).
Findings
Participants demonstrated high willingness to use HDN, motivated by volatility in the local drug supply and perceived inefficiency of naloxone against potent synthetic opioids. Participants believed that the relative advantage of HDN was that it would reverse overdoses more quickly than existing products; however, many participants wanted increased control in overdose situations, including the ability to titrate and combine dosages to reduce the severity of precipitated withdrawal. Skepticism towards HDN products was rooted in general skepticism of pharmaceutical companies, as well as the belief that perceptions of lower dose naloxone being ineffective could be attributed to user error.
Conclusions
Development of novel overdose reversal products should be informed by the experiences of primary consumers and beneficiaries of these products. A high level of transparency is needed in the marketing of these products to promote consumer trust and confidence in their safety and utility.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
- Department of Health, Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
- School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
- College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
- College of Global Public Health, New York University, New York, NY, USA.
ORCID profiles: Laura N Sisson, Lucas G Hill
Funding
- Bloomberg American Health Initiative
Cite
APA
Sisson, L. N., Rousch, R. S., Hill, L. G., Zagorski, C. M., Triece, T., Rouhani, S., Owczarzak, J., Sherman, S. G., & Schneider, K. E. (2026). ‘If you've ever experienced it, you'd feel differently’: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States. Addiction, 121(9), 2494-2503. https://doi.org/10.1111/add.70447
Vancouver
Sisson LN, Rousch RS, Hill LG, Zagorski CM, Triece T, Rouhani S, et al. ‘If you've ever experienced it, you'd feel differently’: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States. Addiction. 2026;121(9):2494-2503. doi:10.1111/add.70447
BibTeX
@article{Sisson2026,
author = {Sisson, Laura N and Rousch, Richard S and Hill, Lucas G and Zagorski, Claire M and Triece, Tricia and Rouhani, Saba and Owczarzak, Jill and Sherman, Susan G and Schneider, Kristin E},
title = {‘If you've ever experienced it, you'd feel differently’: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States},
journal = {Addiction},
year = {2026},
volume = {121},
number = {9},
pages = {2494--2503},
doi = {10.1111/add.70447}
}
EUVIMED